Tarsus Pharmaceuticals, Inc.

As of June 30, 2026, Tarsus Pharmaceuticals, Inc. carries a market capitalization of 2.72B, placing it among publicly traded companies globally. Its enterprise value stands at 2.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Tarsus Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Tarsus Pharmaceuticals, Inc. has 43.27M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 4.46, and the price-to-book ratio stands at 7.85.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.87 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.35B versus a market cap of 2.72B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Tarsus Pharmaceuticals, Inc. maintains a current ratio of 3.20, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 20.99, indicating elevated leverage, while an interest coverage ratio of -5.68 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Tarsus Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -13.68, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -8.40, reflecting losses generated across the asset base. The company generates approximately 1.69M in revenue per employee across its workforce of 358.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 9.88 indicates how many times Tarsus Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Tarsus Pharmaceuticals, Inc. recorded 5.07M in income tax expense. The company reported a pretax loss of -39.35M and -46.48M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Tarsus Pharmaceuticals, Inc.'s stock has gained approximately 4.92% over the past 52 weeks. The 50-day moving average sits at 75.05, while the 200-day moving average is 67.93.

Over the twelve months ended June 30, 2026, Tarsus Pharmaceuticals, Inc. generated 606.33M in revenue and converted that into -46.48M in net income, yielding earnings per share of -1.08. EBITDA reached -46.19M, while operating income came in at -48.53M.

As of June 30, 2026, Tarsus Pharmaceuticals, Inc. holds 449.69M in cash and equivalents against 72.76M in total debt, resulting in a net debt position of -131.83M. Total book value stands at 346.73M, with working capital of 386.24M providing operational flexibility.

Tarsus Pharmaceuticals, Inc. produced 74.16M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -18.15M in capital expenditures, free cash flow totaled 56.00M - equivalent to 1.30 per share.

Over the twelve months ended June 30, 2026, Tarsus Pharmaceuticals, Inc. posted a gross margin of 93.28, reflecting its pricing power and cost economics. The operating margin of -8.00 and net profit margin of -7.67 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 2.07, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.34, meaning Tarsus Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Tarsus Pharmaceuticals, Inc. has an Altman Z-Score of 6.64, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.